News Dismay but little surprise as NICE rejects Alzheimer's drugs Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
News Eisai says patent win blocks Lenvima generic to 2036 Eisai has won a lawsuit blocking FDA approval of Shilpa's generic of cancer blockbuster Lenvima until 2036, although the verdict could go to appeal.
News After delay, Alzheimer's drug Leqembi gets green light in EU The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.
News Gantenerumab 'shows sign of preventing Alzheimer's dementia' A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.
News Eisai to buy "dementia ecosystem" partner EcoNaviSta Eisai's bid to develop an integrated care platform for dementia in Japan has moved forward with the acquisition of remote monitoring firm EcoNaviSta.
News NICE agrees to look again at Alzheimer's drug Leqembi Eisai and Biogen have another chance to convince NICE that the NHS should cover the cost of Alzheimer's therapy Leqembi.
News UK pharma has concerns about the new NHS 10-year plan The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face